The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...
Here are the key chart levels to watch ... the market opens on December 23. Illumina, Inc. (NASDAQ:ILMN) was removed from the index. Year to date, the stock has increased around 8% ...
Shares of Illumina Inc. ILMN shed 1.51% to $100.24 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and Dow ...
Carl Icahn’s Icahn Capital disclosed in an SEC filing its holdings as of December 31, 2024. The fund increased its stakes in two holdings, ...
Shares of genomics company Illumina (NASDAQ:ILMN) fell 7.5% in the morning session after Barclays downgraded the stock to Sell and lowered the price target from $130 to $100. The firm cited ...
Illumina, Inc. (NASDAQ:ILMN – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Wednesday after Morgan Stanley lowered their price target on the stock from $150.00 to ...
On Monday, for the second time in as many business days, Illumina ( ILMN -4.11%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% ...
Shares of Illumina Inc. ILMN shed 5.47% to $104.99 Monday, on what proved to be an all-around favorable trading session for ...
That morning, Barclays changed its recommendation on Illumina stock to underweight (read: sell) from the previous equal weight (hold). It also pulled the lever on a significant price target ...
2d
Hosted on MSNHere's Why Illumina (ILMN) is a Strong Growth StockTaking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...
Shares of genomics company Illumina (NASDAQ:ILMN) fell 7.5% in the morning session after Barclays downgraded the stock to Sell and lowered the price target from $130 to $100. The firm cited several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results